Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women – Findings from HPTN 084 Study

DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) — Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November […] … Read More >Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women – Findings from HPTN 084 Study

Chargebee Enables Subscription Businesses to Combat Economic Turmoil with 2022 Summer Product Release

New Product Launch Leans Heavily on Customer Retention, Monetization and Streamlining Revenue Operations San Francisco, Calif., July 28, 2022 (GLOBE NEWSWIRE) — Chargebee, the leading subscription management platform, today announced its Summer 2022 Product Release. The slate of new products and features is focused on enabling high-performing subscription businesses to monetize their existing customers and […] … Read More >Chargebee Enables Subscription Businesses to Combat Economic Turmoil with 2022 Summer Product Release